No Prescription |
 |
 | ||
|
Zyban Wellbutrin |
|
| ||
No Prescription » Prescription Drugs 17 » Zyban Wellbutrin Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:ZYBAN is indicated as an aid to smoking cessation treatment.Zyban is a prescription medication designed to help smokers quit more easily than without the drug. It comes in a pill form. It does not contain nicotineZyban's history is interesting. Smokers who happened to be users of the anti-depression medication Wellbutrin (bupropion hydrochloride) often reported a lessening in the desire for cigarettes. Through further testing the drug was found to be effective in treating the smoking addiction and helping smokers quit. GlaxoSmithKline "repackaged" Wellbutrin and marketed it as the smoking-cessation drug Zyban. Buy Zyban Wellbutrin and other Prescription Drugs 17 products online at Medstore. 3823
About Zyban Wellbutrin: Product Type: Prescription Drugs 17 Zyban ( Wellbutrin Generic Bupropion ) Zyban (Wellbutrin Generic Bupropion) Wellbutrin Generic Bupropion 150mg 60 Tabs Wellbutrin Generic Bupropion Zyban
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
